LID.L Regulatory News (LID)

LiDCO Group Plc

("LiDCO" or the "Company")

Study shows Haemodynamic Monitoring adds significant benefits to Colorectal Surgery

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, is pleased to see the publication in Anesthesia & Analgesia of a paper from the Enhanced Recovery Study Group at Duke University of North Carolina, titled "Reduced Length of Hospital Stay in Colorectal Surgery from the after Implementation of an Enhanced Recovery Protocol". The study concludes that implementation of an Enhanced Recovery After Surgery ("ERAS") programme for colorectal surgery was associated with a significantly reduced length of stay ("LOS") and incidence of urinary tract infection.

Data were collected from patients undergoing open or laparoscopic colorectal surgery prior to and post the implementation of an ERAS protocol. There were 142 patients in the ERAS group whose outcomes were compared to 99 patients in the traditional care group. Three key outcomes in the study were length of stay post operatively, the incidence of post-operative urinary tract infections and the readmission rates. The median LOS was 5 days in the ERAS group compared with 7 days in the traditional group (P < 0.001). This reduction in LOS was significant for both procedures. ERAS patients had fewer urinary tract infections (13% vs 24%, P = 0.03) and the 30 day readmission rates were lower in ERAS patients (9.8% vs 20.2%, P = 0.02).

All patients received intraoperative goal-directed fluid therapy with a minimally invasive cardiac output monitor. Boluses of IV colloid were given to optimise stroke volume where required. The monitors used were either the Esophageal Doppler (Deltex Medical Group plc) or the LiDCOrapid when invasive arterial blood pressure monitoring was performed. The need for an arterial line was based on the clinical judgment of the anaesthetist in charge of the patient.

Commenting, Terry O'Brien, Chief Executive Officer of LiDCO, said: "The study shows that using haemodynamic monitoring as part of an ERAS programme provides significant benefits to the patient in terms of efficient recovery and for the hospital in terms of the costs related to length of stay, incidence of post-operative infection and need for re-admission post the procedure.

"With the launch of LiDCOrapidv2 in February 2013 we can now also offer an entirely non-invasive solution to provide this new standard of care for all patients undergoing colorectal surgery."

* Paper Referenced: Anesthesia Analgesia 2014; 118:1052-61

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response

· guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapid v2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 

*BISTM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

* CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.